Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Polyarticular-course Juvenile Idiopathic Arthritis
NCT07554495Phase 3Recruiting
- Sponsor
- Alfasigma
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of filgotinib in juvenile idiopathic arthritis (JIA), sponsored by Alfasigma. Started May 2026; status: recruiting.
02
Drugs
filgotinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT07554495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554495.